A specific VEGF-R tyrosine kinase inhibitor enhances the antiproliferative effect of trastuzumab in ErbB-2 overexpressing breast cancer cells

被引：0
|
作者：
Kim, E. [1 ]
Lobocki, C. A. [1 ]
Dubay, L. [1 ]
Mittal, V. [1 ]
机构：
[1] Providence Hosp, Med Ctr, Southfield, MI 48037 USA
来源：
ANNALS OF SURGICAL ONCOLOGY | 2007年 / 14卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：48 / 49
页数：2
相关论文
共 50 条
  • [31] Effect of dasatinib on the activity of trastuzumab in HER2-overexpressing breast cancer cells
    Seoane, S.
    Montero, J. C.
    Pandiella, A.
    Ocana, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [32] A potential for combining the mTOR inhibitor RAD001 (everolimus) with the ErbB2 receptor tyrosine kinase inhibitory antibody trastuzumab in breast cancer
    Lane, H.
    Stephan, C.
    Zumstein-Mecker, S.
    Welsch, A.
    Tinetto, W.
    Klopfenstein, M.
    Chateny-Rivauday, C.
    O'Reilly, T.
    Hynes, N.
    Baselga, J.
    EJC SUPPLEMENTS, 2006, 4 (12): : 175 - 175
  • [33] Ganetespib targets multiple levels of the receptor tyrosine kinase signaling cascade and preferentially inhibits ErbB2-overexpressing breast cancer cells
    Harry Lee
    Nipun Saini
    Erin W. Howard
    Amanda B. Parris
    Zhikun Ma
    Qingxia Zhao
    Ming Zhao
    Bolin Liu
    Susan M. Edgerton
    Ann D. Thor
    Xiaohe Yang
    Scientific Reports, 8
  • [34] Ganetespib targets multiple levels of the receptor tyrosine kinase signaling cascade and preferentially inhibits ErbB2-overexpressing breast cancer cells
    Lee, Harry
    Saini, Nipun
    Howard, Erin W.
    Parris, Amanda B.
    Ma, Zhikun
    Zhao, Qingxia
    Zhao, Ming
    Liu, Bolin
    Edgerton, Susan M.
    Thorn, Ann D.
    Yang, Xiaohe
    SCIENTIFIC REPORTS, 2018, 8
  • [35] Differential effects of erbB3 and IGF-1R signaling on lapatinib resistance acquired by the erbB2-overexpressing breast cancer cells refractory to trastuzumab
    Lyu, Hui
    Huang, Jingcao
    Lee, Youngseok
    Liu, Bolin
    MOLECULAR CANCER RESEARCH, 2013, 11
  • [36] Transforming growth factor β engages TACE and ErbB3 to activate phosphatidylinositol-3 kinase/Akt in ErbB2-overexpressing breast cancer and desensitizes cells to trastuzumab
    Wang, Shizhen Emily
    Xian, Bin
    Guix, Marta
    Olivares, Maria Graciela
    Parker, Joel
    Chung, Christine H.
    Pandiella, Atanasio
    Arteaga, Carlos L.
    MOLECULAR AND CELLULAR BIOLOGY, 2008, 28 (18) : 5605 - 5620
  • [37] The dual EGFR and ErbB-2 tyrosine kinase inhibitor NVP-AEE788 - a new approach for the therapy of biliary tract cancer?
    Wiedmann, Marcus
    Feisthammel, Juergen
    Bluethner, Thilo
    Tannapfel, Andrea
    Witzigmann, Helmut
    Serr, Frederik
    Moessner, Joachim
    Caca, Karel
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2006, 21 : A164 - A164
  • [38] Trastuzumab signaling in ErbB2-overexpressing inflammatory breast cancer correlates with X-linked inhibitor of apoptosis protein expression
    Aird, Katherine M.
    Ding, Xiuyun
    Baras, Aris
    Wei, Junping
    Morse, Michael A.
    Clay, Timothy
    Lyerly, Herbert K.
    Devi, Gayathri R.
    MOLECULAR CANCER THERAPEUTICS, 2008, 7 (01) : 38 - 47
  • [39] ErbB1/2 tyrosine kinase inhibitor mediates oxidative stress-induced apoptosis in inflammatory breast cancer cells
    Aird, Katherine M.
    Allensworth, Jennifer L.
    Batinic-Haberle, Ines
    Lyerly, H. Kim
    Dewhirst, Mark W.
    Devi, Gayathri R.
    BREAST CANCER RESEARCH AND TREATMENT, 2012, 132 (01) : 109 - 119
  • [40] ErbB1/2 tyrosine kinase inhibitor mediates oxidative stress-induced apoptosis in inflammatory breast cancer cells
    Katherine M. Aird
    Jennifer L. Allensworth
    Ines Batinic-Haberle
    H. Kim Lyerly
    Mark W. Dewhirst
    Gayathri R. Devi
    Breast Cancer Research and Treatment, 2012, 132 : 109 - 119
12345